

Correction: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort

Tomi Akinyemiju¹, Justin X. Moore², Daniel Tefera Dibaba³, Maria Pisu⁴, Michael Goodman⁵, Virginia J. Howard⁶, Monika Safford⁷, Susan C. Gilchrist⁸, Mary Cushman⁹, LeAnn Long¹⁰ and Suzanne E. Judd¹⁰

¹Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA

²Division of Public Health Sciences and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

³Tennessee Clinical and Translational Science Institute, University of Tennessee Health Science Center, Memphis, TN, USA

⁴Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham AL, USA

⁵Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA

⁶Department of Epidemiology, University of Alabama at Birmingham, Birmingham AL, USA

⁷Department of Medicine, Weill Cornell Medical College, New York, NY, USA

⁸Department of Clinical Cancer Prevention and Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁹Department of Medicine and Vermont Cancer Center, Larner College of Medicine at the University of Vermont, Burlington, VT, USA

¹⁰Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

Published: February 18, 2020

Copyright: Akinyemiju et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The third author in the listing, along with a new affiliation, has been added as follows:

Daniel Tefera Dibaba³

³Tennessee Clinical and Translational Science Institute, University of Tennessee Health Science Center, Memphis, TN, USA

Original article: Oncotarget. 2019; 10:4857–4867. <https://doi.org/10.18632/oncotarget.27108>